Keith E Stockerl-Goldstein MD

Hematologic Oncology

Professor of Medicine BMT/Leukemia Program

4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSt. Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902

Dr. Stockerl-Goldstein is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stockerl-Goldstein's full profile Already have an account?

Summary

Keith Stockerl-Goldstein, MD, is an oncology specialist located in St. Louis, MO, with a subspecialty in hematologic oncology. He completed his residency in Internal Medicine and his fellowship in Medical Oncology and BMT at Stanford University. He is a Professor of Medicine at WashU Medicine. His expertise includes amyloidosis, multiple myeloma, hematologic malignancies, hematopoietic stem cell transplantation and cellular therapy. Dr. Stockerl-Goldstein has authored numerous publications in reputed journals and has been involved in multiple clinical trials, with a focus on multiple myeloma and light chain amyloidosis.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1993 - 1996
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1991 - 1993
David Geffen School of Medicine at UCLAClass of 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MO State Medical License 2007 - 2027
IL State Medical License 2020 - 2026
CA State Medical License 1993 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017

Clinical Trials

Mixed Chimeric Transplantation for Primary Amyloidosis
WITHDRAWN
NA
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
ACTIVE_NOT_RECRUITING
PHASE2
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.
Rakesh Popat, Bradley Augustson, Paul Cannell, Keith Stockerl-Goldstein, Andrew Spencer
Clinical Cancer Research. 2026-05-15
2 citations
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib.
Ashley Jones, Samuele Bonomi, Keith E Stockerl-Goldstein, Randall J Bateman
Annals of Clinical and Translational Neurology. 2026-04-01
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous ...
Zachary D Crees, Keith Stockerl-Goldstein, Meaghan Ryan, Feng Gao, Brandon Christen
Transplantation and Cellular Therapy. 2026-03-01

Abstracts/Posters

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Keith E. Stockerl-Goldstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
Keith E. Stockerl-Goldstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell TransplantationMay 26th, 2021
Drug Combination Shows Promise for Newly Diagnosed Blood Cancer Patients, Study FindsDecember 11th, 2010